Ligand id: 8948

Name: AZD5069

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 158.56
Molecular weight 476.1
XLogP 1.69
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
AZD5069 is being evaluated in Phase 2 clinical trials for inflammatory conditions and oncology indications. Results of a trial in patients with bronchiectasis have been reported [2]. For a list of all current trials, visit Trials combining AZD5069 with the anti-PD-L1 immune checkpoint inhibitor durvalumab are underway in patients with metastatic pancreatic ductal adenocarcinoma (NCT02583477, Phase 1/2) and metastatic squamous cell carcinoma of the head and neck and other solid tumours (NCT02499328, Phase 1/2).